X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abiraterone acetate (1251) 1251
humans (1226) 1226
prostate cancer (1216) 1216
male (1168) 1168
oncology (844) 844
abiraterone (755) 755
enzalutamide (639) 639
docetaxel (579) 579
chemotherapy (574) 574
prostatic neoplasms, castration-resistant - drug therapy (564) 564
metastasis (505) 505
urology & nephrology (502) 502
increased survival (431) 431
cancer (417) 417
aged (374) 374
survival (362) 362
care and treatment (347) 347
treatment outcome (340) 340
antineoplastic agents - therapeutic use (337) 337
prostatic neoplasms - drug therapy (331) 331
double-blind (328) 328
prostatic neoplasms, castration-resistant - pathology (328) 328
androgen receptor (320) 320
castration (318) 318
middle aged (314) 314
androgens (302) 302
antitumor-activity (296) 296
castration-resistant prostate cancer (294) 294
men (293) 293
prednisone (262) 262
phenylthiohydantoin - analogs & derivatives (241) 241
aged, 80 and over (231) 231
therapy (219) 219
prostate (215) 215
prostatic neoplasms - pathology (214) 214
mitoxantrone (204) 204
metastases (203) 203
pharmacology & pharmacy (201) 201
urology (200) 200
cabazitaxel (199) 199
mitoxantrone plus prednisone (198) 198
neoplasm metastasis (198) 198
survival analysis (198) 198
androgen antagonists - therapeutic use (190) 190
research (190) 190
cancer therapies (185) 185
patients (179) 179
taxoids - therapeutic use (178) 178
plus prednisone (177) 177
antineoplastic combined chemotherapy protocols - therapeutic use (170) 170
analysis (168) 168
drug therapy (168) 168
receptors, androgen - metabolism (167) 167
disease-free survival (166) 166
phenylthiohydantoin - therapeutic use (166) 166
animals (161) 161
disease progression (158) 158
retrospective studies (155) 155
prognosis (152) 152
medicine & public health (145) 145
health aspects (141) 141
testosterone (140) 140
metastatic castration-resistant prostate cancer (139) 139
orchiectomy (136) 136
endocrinology & metabolism (135) 135
clinical trials (132) 132
resistant prostate-cancer (130) 130
development and progression (129) 129
sipuleucel-t (129) 129
abiraterone acetate - therapeutic use (126) 126
cyp17 (126) 126
prostate-specific antigen - blood (125) 125
prostatic neoplasms - metabolism (124) 124
androgen-deprivation therapy (122) 122
prostatic neoplasms, castration-resistant - blood (119) 119
open-label (118) 118
progression (117) 117
prostatic neoplasms, castration-resistant - mortality (117) 117
androgen deprivation therapy (115) 115
drug resistance, neoplasm (114) 114
immunotherapy (113) 113
steroid 17-alpha-hydroxylase - antagonists & inhibitors (110) 110
trial (110) 110
antineoplastic agents, hormonal - therapeutic use (109) 109
hematology, oncology and palliative medicine (108) 108
i clinical-trial (106) 106
androstenes (105) 105
urologic and male genital diseases (105) 105
expression (103) 103
cell line, tumor (102) 102
prostatic neoplasms, castration-resistant - metabolism (102) 102
acetate (101) 101
bone neoplasms - secondary (101) 101
prostatic neoplasms - therapy (101) 101
receptors, androgen - genetics (101) 101
phase-ii (100) 100
inhibitor (98) 98
clinical-trials (96) 96
prostate-specific antigen (96) 96
review (96) 96
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1850) 1850
German (55) 55
French (51) 51
Spanish (19) 19
Russian (14) 14
Japanese (6) 6
Portuguese (4) 4
Dutch (3) 3
Chinese (2) 2
Italian (2) 2
Czech (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
European urology, ISSN 0302-2838, 2014, Volume 66, Issue 5, pp. 815 - 825
Abstract Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC... 
Urology | Chemotherapy-naive | Efficacy | Safety | Metastatic castration-resistant prostate cancer | Abiraterone acetate | prostate cancer | Metastatic castration-resistant | PLACEBO | DOCETAXEL CHEMOTHERAPY | PHASE-3 | TRIAL | MITOXANTRONE PLUS PREDNISONE | THERAPY | MEN | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | LIFE | Neoplasms, Hormone-Dependent - mortality | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Abiraterone Acetate | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Neoplasms, Hormone-Dependent - enzymology | Prednisone - administration & dosage | Androstenes - adverse effects | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androstenes - administration & dosage | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Neoplasms, Hormone-Dependent - drug therapy | Medical colleges | Cancer patients | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Metastasis | Prostate cancer | Acetates | Cancer
Journal Article
European urology, ISSN 0302-2838, 2015, Volume 67, Issue 4, pp. 795 - 802
Journal Article
BMC cancer, ISSN 1471-2407, 2017, Volume 17, Issue 1, pp. 753 - 753
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 4, pp. 338 - 351
Journal Article
BMC CANCER, ISSN 1471-2407, 05/2019, Volume 19, Issue 1, pp. 487 - 8
Journal Article
Clinical cancer research, ISSN 1557-3265, 2017, Volume 23, Issue 22, pp. 6812 - 6822
Journal Article
Journal Article